Core Viewpoint - Intuitive Surgical, Inc. (ISRG) is facing challenges in the market despite its strong revenue growth and profitability improvements, with its stock underperforming compared to broader indices over the past year [2][4]. Company Overview - Intuitive Surgical, Inc. is valued at a market cap of $172.5 billion and specializes in robotic-assisted surgical systems and related digital solutions for minimally invasive procedures [1]. Market Performance - Over the past 52 weeks, ISRG shares have declined by 17.9%, while the S&P 500 Index has gained 11.8% [2]. - Year-to-date, ISRG's stock is down 14.2%, contrasting with a slight dip in the S&P 500 [2]. - ISRG has also underperformed compared to the State Street SPDR S&P Health Care Equipment ETF, which saw an 8.3% decline over the past year [3]. Financial Performance - For fiscal Q4 2025, ISRG reported a revenue increase of 19% year-over-year, reaching $2.87 billion, driven by higher procedure volumes and increased placements of da Vinci systems [4]. - Revenue from instruments and accessories rose by 17% to $1.66 billion, with da Vinci procedures growing by 17% and Ion procedures by 44% [4]. - Systems revenue increased to $786 million due to higher placements and average selling prices [4]. - Non-GAAP operating income improved to $1.07 billion, with non-GAAP earnings per share at $2.53, aided by tax benefits [5]. - The company ended the quarter with $9.03 billion in cash, cash equivalents, and investments [5]. Future Outlook - For 2026, Intuitive expects worldwide da Vinci procedure growth of 13% to 15% and a non-GAAP gross margin of 67% to 68% of revenue, factoring in tariff impacts [5]. - Analysts project ISRG's EPS to rise by 13.9% year-over-year to $8.22 for the current fiscal year ending in December [6]. - The company has a strong earnings surprise history, exceeding consensus estimates in each of the last four quarters [6].

Core Insights - Intuitive Surgical reported strong fourth-quarter earnings and revenue, surpassing analyst expectations, driven by growth in da Vinci and Ion procedures [1][2] Financial Performance - Adjusted earnings per share reached $2.53, exceeding the consensus estimate of $2.26 [1] - Revenue increased to $2.87 billion, surpassing expectations of $2.75 billion, marking a 19% rise from $2.41 billion in the same quarter last year [1] Procedure Growth - Da Vinci procedures grew by 17%, while Ion procedures saw a significant increase of 44% during the quarter [2] - The company placed 532 da Vinci systems in the quarter, up from 493 a year earlier, expanding the installed base to 11,106 systems, a 12% year-over-year increase [2] Revenue Breakdown - Revenue from instruments and accessories rose 17% to $1.66 billion [2] - Systems revenue increased to $786 million from $655 million in the prior-year quarter [2] Future Outlook - The company forecasts worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, a decrease from 18% growth projected for 2025 [3] - Intuitive Surgical anticipates a non-GAAP gross profit margin of 67% to 68% of revenue, factoring in an estimated 1.2 percentage point impact from tariffs [3]